title: Effects of NKH477, a forskolin derivative, and dibutyryl-cyclic AMP on adrenal catecholamine release in response to splanchnic nerve stimulation, acetylcholine, DMPP and muscarine in anesthetized dogs.
abstract: The effects of NKH477, a water-soluble forskolin derivative, and dibutyryl-cyclic adenosine monophosphate (dbcAMP) on the release of adrenal catecholamines (CAs) in response to splanchnic nerve stimulation (SNS), acetylcholine (ACh), the nicotinic receptor stimulant 1,1-dimethyl-4-phenyl-piperazinium iodide (DMPP) and muscarine were examined in anesthetized dogs. NKH477, dbcAMP and the cholinergic agonists were infused and injected, respectively, into the adrenal gland intra-arterially. SNS (3 Hz) or injections of ACh (3 micrograms), DMPP (2 micrograms) and muscarine (2 micrograms) produced increases in CA output determined from adrenal venous blood. Both NKH477 infusion (0.3, 1 and 3 micrograms/min) and dbcAMP infusion (0.1, 0.3 and 1 mg/min) caused dose-dependent enhancement of the SNS-, ACh- and DMPP-induced increases in CA output, whereas they failed to affect the muscarine-induced increases in CA output. Neither NKH477 nor dbcAMP affected basal CA output. Cyclic AMP (cAMP) overflow determined from adrenal venous blood increased during NKH477 infusion. These results indicate that NKH477 and dbcAMP have facilitatory effects on adrenal CA release mediated by nicotinic receptors, but not by muscarinic receptors in the dog, and suggest the selective action of cAMP on nicotinic mechanism.
authors.affiliation: Department Of Pharmacology, Tohoku University, Aobayama, Sendai, Japan.
authors.forename: T
authors.initials: T
authors.lastname: Koshika
authors.forename: T
authors.initials: T
authors.lastname: Nagayama
authors.forename: Y
authors.initials: Y
authors.lastname: Iizuka
authors.forename: T
authors.initials: T
authors.lastname: Kimura
authors.forename: S
authors.initials: S
authors.lastname: Satoh
mesh_terms: D000109:Acetylcholine / Q000494:pharmacology; D000311:Adrenal Glands / Q000187:drug effects* / Q000378:metabolism; D000818:Animals; D003994:Bucladesine / Q000008:administration & dosage / Q000494:pharmacology*; D002395:Catecholamines / Q000097:blood*; D005576:Colforsin / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology; D004246:Dimethylphenylpiperazinium Iodide / Q000494:pharmacology; D004285:Dogs; D005260:Female; D007261:Infusions, Intra-Arterial; D007269:Injections, Intra-Arterial; D008297:Male; D009116:Muscarine / Q000494:pharmacology; D018721:Muscarinic Agonists / Q000494:pharmacology; D011978:Receptors, Nicotinic / Q000187:drug effects; D013153:Splanchnic Nerves / Q000502:physiology; D014665:Vasodilator Agents / Q000008:administration & dosage / Q000494:pharmacology*
chemical_list: D002395:Catecholamines; D018721:Muscarinic Agonists; D011978:Receptors, Nicotinic; D014665:Vasodilator Agents; D005576:Colforsin; D004246:Dimethylphenylpiperazinium Iodide; D003994:Bucladesine; D009116:Muscarine; D000109:Acetylcholine